Study Information

Study Title

A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients with First-Line, Locally-Advanced, or Metastatic EGFR-mutated NSCLC Treated with Amivantamab + Lazertinib (COCOON Study)

Study Summary

The purpose of this clinical trial is to evaluate whether enhanced dermatologic management can reduce incidence of Grade ≥2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic Stage IIB/C-IV EGFR-mutated NSCLC treated first-line with amivantamab and lazertinib.

Disease State

EGFR-Mutated Non-Small Cell Lung Cancer

Principal Investigator

Waqas Rehman, MD

Phase II

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.